| 1. |
|
|
| 2. |
- Bauer, C., et al.
(författare)
-
Prolate shape of Ba-140 from a first combined Doppler-shift and Coulomb-excitation measurement at the REX-ISOLDE facility
- 2012
-
Ingår i: Physical Review C (Nuclear Physics). - 0556-2813. ; 86:3
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Quadrupole moments of excited nuclear states are important observables for geometrically interpreting nuclear structure in terms of deformed shapes, although data are scarce and sometimes ambiguous, in particular, in neutron-rich nuclides. Purpose: A measurement was performed for determining the spectroscopic quadrupole moment of the 2(1)(+) state of Ba-140 in order to clarify the character of quadrupole deformation (prolate or oblate) of the state in its yrast sequence of levels. Method: We have utilized a new combined technique of lifetime measurement at REX-ISOLDE and MINIBALL using the Doppler-shift attenuation method (DSAM) and a reorientation analysis of Coulomb-excitation yields. Results: On the basis of the new lifetime of tau(2(1)(+)) = 10.4(-0.8)(+2.2) ps the electric quadrupole moment was determined to be Q(2(1)(+)) = -0.52(34) eb, indicating a predominant prolate deformation. Conclusions: This finding is in agreement with beyond-mean-field calculations using the Gogny D1S force and with results from the Monte Carlo shell-model approach.
|
|
| 3. |
- Kröll, Th, et al.
(författare)
-
Quadrupole Collectivity of neutron-rich nuclei around 132Sn
- 2008
-
Ingår i: Frontiers in Nuclear Structure, Astrophysics, and Reactions, FINUSTAR 2007. - : AIP. - 9780735405325 ; 1012, s. 296-299
-
Konferensbidrag (refereegranskat)abstract
- We report on the "safe" Coulomb excitation of neutron-rich Cd, Xe, and Ba isotopes in the vicinity of the doubly-magic nucleus 132Sn. The radioactive nuclei have been produced by ISOLDE at CERN and postaccelerated by the REX-ISOLDE facility. The γ-decay of excited states has been detected by the MINIBALL array. The presented preliminary results for the B(E2) values are consistent with expectations from phenomenological systematics and will be compared with theoretical calculations.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Ray-Coquard, I., et al.
(författare)
-
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer
- 2020
-
Ingår i: International Journal of Cancer. - : John Wiley & Sons. - 0020-7136 .- 1097-0215. ; 146:2, s. 439-448
-
Tidskriftsartikel (refereegranskat)abstract
- AGO-OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor nintedanib to standard front-line chemotherapy for advanced ovarian cancer. At the primary analysis, nintedanib demonstrated significantly improved progression-free survival (PFS; primary endpoint) compared with placebo. We report final results, including overall survival (OS). Patients with primary debulked International Federation of Gynaecology and Obstetrics (FIGO) stage IIB–IV newly diagnosed ovarian cancer were randomised 2:1 to receive carboplatin (area under the curve 5 or 6) plus paclitaxel (175 mg/m2) on day 1 every 3 weeks for six cycles combined with either nintedanib 200 mg or placebo twice daily on days 2–21 every 3 weeks for up to 120 weeks. Between December 2009 and July 2011, 1,366 patients were randomised (911 to nintedanib, 455 to placebo). Disease was considered as high risk (FIGO stage III with amp;gt;1 cm residuum, or any stage IV) in 39%. At the final analysis, 605 patients (44%) had died. There was no difference in OS (hazard ratio 0.99, 95% confidence interval [CI] 0.83–1.17, p = 0.86; median 62.0 months with nintedanib vs. 62.8 months with placebo). Subgroup analyses according to stratification factors, clinical characteristics and risk status showed no OS difference between treatments. The previously reported PFS improvement seen with nintedanib did not translate into an OS benefit in the nonhigh-risk subgroup. Updated PFS results were consistent with the primary analysis (hazard ratio 0.86, 95% CI 0.75–0.98; p = 0.029) favouring nintedanib. The safety profile was consistent with previous reports. © 2019 UICC
|
|
| 7. |
|
|
